Christopher Russell, MD, MS (he/his/him)
@cjrussellmd.bsky.social
Associate Professor, Pediatric Hospitalist, Stanford Medicine Children’s Health. Physician-scientist & clinical researcher studying children with medical complexity. Views my own. 🏳️🌈
More at https://med.stanford.edu/profiles/314127
More at https://med.stanford.edu/profiles/314127
🚨🚨Please amplify and consider joining the lawsuit or submitting an amicus brief: @academyhealth.bsky.social @atscommunity.bsky.social @ats-peds.bsky.social @ameracadpeds.bsky.social
September 7, 2025 at 2:23 AM
🚨🚨Please amplify and consider joining the lawsuit or submitting an amicus brief: @academyhealth.bsky.social @atscommunity.bsky.social @ats-peds.bsky.social @ameracadpeds.bsky.social
Or be clear in the abstract that it was underpowered (understanding that this was not due to any fault of the investigators). However, noting this as a randomized, multicenter, double-blinded study in the title but not acknowledging that it was underpowered in the abstract is concerning.
January 30, 2025 at 6:40 PM
Or be clear in the abstract that it was underpowered (understanding that this was not due to any fault of the investigators). However, noting this as a randomized, multicenter, double-blinded study in the title but not acknowledging that it was underpowered in the abstract is concerning.
Can’t reliably estimate the rare outcomes if you are so underpowered. IMO, underpowered RCTs, particularly those with null findings or non-inferiority design, should rarely be published. People see RCT and think high level of evidence, and assume the conclusions are sound.
January 30, 2025 at 6:40 PM
Can’t reliably estimate the rare outcomes if you are so underpowered. IMO, underpowered RCTs, particularly those with null findings or non-inferiority design, should rarely be published. People see RCT and think high level of evidence, and assume the conclusions are sound.
They also (incorrectly) state in the abstract that “Placebo appears to be non-inferior to amoxicillin in reducing fever duration” but then correctly say in the discussion that they “must reject the hypothesis of non-inferiority of placebo over amoxicillin.” Can’t move the goal posts…
January 30, 2025 at 6:27 PM
They also (incorrectly) state in the abstract that “Placebo appears to be non-inferior to amoxicillin in reducing fever duration” but then correctly say in the discussion that they “must reject the hypothesis of non-inferiority of placebo over amoxicillin.” Can’t move the goal posts…
The primary outcome is odd—fever duration—and they are quite underpowered to detect differences in adverse events. The adverse events aren’t benign (~3% in placebo with RPA), which may have been prevented by upfront treatment. Not sure how to use this in my practice.
January 30, 2025 at 6:20 PM
The primary outcome is odd—fever duration—and they are quite underpowered to detect differences in adverse events. The adverse events aren’t benign (~3% in placebo with RPA), which may have been prevented by upfront treatment. Not sure how to use this in my practice.